Russia Cancer Vaccine Enteromix Shows 100% Success in Trials, according to optimistic statements from developers. The claim highlights notable preclinical results.
Enteromix, a novel oncolytic vaccine, began Phase I clinical trials in mid-2025. The National Medical Research Radiological Center in Saint Petersburg oversees the study with 48 volunteers recruited so far. The vaccine showed very low toxicity in these early stages
Russia Cancer Vaccine Enteromix Shows 100% Success in Trials, especially in preclinical studies, where tumor destruction ranged from slowing growth to complete removal. These results suggest strong potential However, no human trial has confirmed 100% success yet.
Enteromix uses a combination of four non-pathogenic viruses. These viruses attack malignant cells and also stimulate the patient’s antitumor immune response. This dual mechanism makes it a promising therapy.
Selection for trial participants began in late 2024. Eligible patients are adults with solid tumors for whom standard treatments no longer work. Participation is free
An mRNA-based version of Enteromix is also in development. It is personalized by analyzing tumor genetics and tailoring the vaccine accordingly. This personalized approach may expand treatment options and improve outcomes.
The vaccine has drawn international interest. Russia’s Health Minister confirmed that other countries have shown demand for the therapy. Entry into clinical use is expected soon, pending regulatory approval.
Still, experts urge caution. The “100% success” claim refers to preclinical results. Human trials are just beginning. Long-term results remain unknown
Read More : UK Patients Join First mRNA Cancer Vaccine Trials
